We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
ZURICH--Novartis AG (NVS) said Monday the European Commission had approved its Simbrinza eye drops for use in patients with the sight-threatening disease glaucoma.
Simbrinza, made by the Basel-based pharmaceutical giant's Alcon eyecare unit, doesn't contain beta blockers, a class of drugs that is often used to ease pressure in the eye, but can't be used by some glaucoma patients suffering from certain respiratory or heart ailments.
Glaucoma describes a group of eye conditions that impair human vision. It is one of the main causes of blindness around the world.
Simbrinza will be available in the U.K. in the third quarter, Novartis said. Other European markets will follow later in 2014 and 2015.
The U.S. Food and Drug Administration has already approved Simbrinza, which has been on the market in the U.S. since 2013.
Write to neil.maclucas@wsj.com
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
